{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Islet+Cell+Carcinoma&page=3", "query": { "condition": "Pancreatic Islet Cell Carcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 80, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Islet+Cell+Carcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Islet+Cell+Carcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T20:32:36.527Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02231723", "title": "A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "BBI608", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "MM-398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2014-08", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02231723" }, { "nct_id": "NCT00019786", "title": "Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Islet Cell Tumor", "Liver Cancer", "Metastatic Cancer", "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "isolated perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 67, "start_date": "1999-08", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2012-03-23", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019786" }, { "nct_id": "NCT00096083", "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "isolated perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 56, "start_date": "2004-09", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096083" }, { "nct_id": "NCT00006368", "title": "Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Breast Cancer", "Gastrointestinal Carcinoid Tumor", "Islet Cell Tumor", "Lung Cancer", "Lymphoma", "Melanoma (Skin)", "Neoplastic Syndrome" ], "interventions": [ { "name": "yttrium Y 90-edotreotide", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1998-01", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2013-05-01", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006368" }, { "nct_id": "NCT01365169", "title": "Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Head and Neck Neoplasm", "Malignant Neoplasm", "Metastatic Malignant Neoplasm in the Neck", "Metastatic Malignant Neoplasm in the Uterine Cervix", "Pancreatic Adenocarcinoma", "Pancreatic Neuroendocrine Carcinoma", "Recurrent Colorectal Carcinoma", "Stage I Colorectal Cancer AJCC v6 and v7", "Stage I Hypopharyngeal Carcinoma AJCC v7", "Stage I Major Salivary Gland Cancer AJCC v7", "Stage I Nasopharyngeal Carcinoma AJCC v7", "Stage I Oral Cavity Cancer AJCC v6 and v7", "Stage I Oropharyngeal Carcinoma AJCC v6 and v7", "Stage II Colorectal Cancer AJCC v7", "Stage II Hypopharyngeal Carcinoma AJCC v6 and v7", "Stage II Major Salivary Gland Cancer AJCC v7", "Stage II Nasopharyngeal Carcinoma AJCC v7", "Stage II Oral Cavity Cancer AJCC v6 and v7", "Stage II Oropharyngeal Carcinoma AJCC v6 and v7", "Stage IIA Colorectal Cancer AJCC v7", "Stage IIB Colorectal Cancer AJCC v7", "Stage IIC Colorectal Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Hypopharyngeal Carcinoma AJCC v7", "Stage III Laryngeal Cancer AJCC v6 and v7", "Stage III Major Salivary Gland Cancer AJCC v7", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage III Oral Cavity Cancer AJCC v6 and v7", "Stage III Oropharyngeal Carcinoma AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVA Hypopharyngeal Carcinoma AJCC v7", "Stage IVA Laryngeal Cancer AJCC v7", "Stage IVA Major Salivary Gland Cancer AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVA Oral Cavity Cancer AJCC v6 and v7", "Stage IVA Oropharyngeal Carcinoma AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Stage IVB Hypopharyngeal Carcinoma AJCC v7", "Stage IVB Laryngeal Cancer AJCC v7", "Stage IVB Major Salivary Gland Cancer AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Oral Cavity Cancer AJCC v6 and v7", "Stage IVB Oropharyngeal Carcinoma AJCC v7", "Metastatic or Locally Unresectable Solid Tumor" ], "interventions": [ { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Health Telemonitoring", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2011-05-25", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01365169" }, { "nct_id": "NCT00084461", "title": "Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrinoma", "Glucagonoma", "Insulinoma", "Metastatic Gastrointestinal Carcinoid Tumor", "Pancreatic Polypeptide Tumor", "Pulmonary Carcinoid Tumor", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Regional Gastrointestinal Carcinoid Tumor", "Somatostatinoma" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084461" }, { "nct_id": "NCT00454363", "title": "Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrin-Producing Neuroendocrine Tumor", "Lung Carcinoid Tumor", "Metastatic Digestive System Neuroendocrine Tumor G1", "Multiple Endocrine Neoplasia Type 1", "Pancreatic Glucagonoma", "Pancreatic Insulinoma", "Pancreatic Polypeptide Tumor", "Recurrent Digestive System Neuroendocrine Tumor G1", "Recurrent Pancreatic Neuroendocrine Carcinoma", "Regional Digestive System Neuroendocrine Tumor G1", "Somatostatin-Producing Neuroendocrine Tumor" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 52, "start_date": "2007-03", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2020-04-03", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00454363" }, { "nct_id": "NCT00325104", "title": "Cinacalcet to Treat Familial Primary Hyperparathyroidism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercalcemia", "Familial Primary Hyperparathyroidism" ], "interventions": [ { "name": "Parathyroid hormone testing", "type": "PROCEDURE" }, { "name": "Serum calcium testing", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-05-09", "completion_date": "2007-03-31", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00325104" }, { "nct_id": "NCT02038738", "title": "68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroendocrine", "Neuroendocrine Tumor", "Neuroendocrine Cancer", "Neuroendocrine Carcinoma", "Carcinoid", "Carcinoid Tumor", "Islet Cell Tumor", "Apudoma" ], "interventions": [ { "name": "68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ochsner Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2014-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 1, "location_summary": "Kenner, Louisiana", "locations": [ { "city": "Kenner", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02038738" }, { "nct_id": "NCT01980732", "title": "68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Carcinoid Tumors", "Islet Cell (Pancreatic NET)", "Other Neuroendocrine Tumors" ], "interventions": [ { "name": "68Ga-DOTA TATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrei Iagaru", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2017-08-23", "last_synced_at": "2026-10-09T20:32:36.527Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01980732" } ] }